Please assess the completion status of the following clinical trial:

Trial Title: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age~* relapsed CD20+ indolent B-cell non-Hodgkin's lymphoma~* documented history of response of \>/= 6 months duration from last rituximab-containing regimen~* clinical indication for treatment as determined by the investigator~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~Exclusion Criteria:~* prior use of any investigational monoclonal antibody within 6 months of study start~* prior use of any anti-cancer vaccine~* prior use of rituximab within 8 weeks of study entry~* radioimmunotherapy within 3 months prior to study entry~* Central Nervous System (CNS) lymphoma or evidence of transformation to high-grade or diffuse large B-cell lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Obinutuzumab (Type: EXPERIMENTAL): Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
- Rituximab (Type: ACTIVE_COMPARATOR): Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).